X0609 4 2026-07-09 0001650648 4D Molecular Therapeutics, Inc. FDMT 0001834021 Kirn David false C/O 4D MOLECULAR THERAPEUTICS INC. 5858 HORTON STREET #455 EMERYVILLE CA 94608 true true false false See Remarks true Common Stock 2026-07-09 4 S false 42608 12.8656 D 899877 D Common Stock 2026-07-10 4 S false 15283 12.0107 D 884594 D Common Stock 2026-07-10 4 S false 442 12.8355 D 884152 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. The transaction was executed in multiple trades in prices ranging from $12.68 to $13.23, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades in prices ranging from $11.575 to $12.49, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades in prices ranging from $12.82 to $12.88, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. President and Chief Executive Officer /s/ Scott Bizily as Attorney-in-Fact for David Kirn 2026-07-14